SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Opioid receptors, including delta (δ), mu (μ), and kappa (κ), are key targets for pain management.
• Selective agonists for specific opioid receptor subtypes are sought to optimize therapeutic effects and minimize side effects.
• SNC 80 is a nonpeptidic compound investigated for its potential as a selective delta-opioid receptor agonist.

Purpose of the Study:

• To investigate the pharmacological profile of SNC 80.
• To determine the selectivity of SNC 80 for delta-opioid receptors over mu and kappa receptors.
• To evaluate the antinociceptive (pain-reducing) effects of SNC 80 in vivo.

Main Methods:

• In vitro assays using mouse vas deferens and guinea pig ileum to assess contractile inhibition.
• Radioligand binding assays using mouse whole-brain preparations to determine receptor affinity.
• In vivo antinociception tests (warm-water tail-flick and hot-plate tests) following various administration routes (intracerebroventricular, intrathecal, intraperitoneal).

Main Results:

• SNC 80 potently inhibited contractions of the mouse vas deferens (delta-rich tissue) but not the guinea pig ileum (mu-rich tissue).
• Selective antagonists confirmed the delta-mediated action in the mouse vas deferens.
• Radioligand binding assays showed significantly higher affinity of SNC 80 for delta receptors compared to mu and kappa receptors (mu/delta Ki ratio = 495, kappa/delta Ki ratio = 248).
• SNC 80 produced dose- and time-dependent antinociception in both warm-water tail-flick and hot-plate tests across different administration routes.

Conclusions:

• SNC 80 acts as a potent and selective delta-opioid receptor agonist in vitro and in vivo.
• The compound exhibits significant antinociceptive efficacy in preclinical models.
• SNC 80 represents a promising nonpeptidic delta-selective agonist for potential therapeutic applications in pain relief.